The treatment of the clinically significant macular edema in patients with diabetic maculopathy by the intravitreal administration of corticosteroids and antiangiogenic factors requires rapid and more accurate investigation methods aimed at following up the dynamic evolution of the structural parameters of the retina. The purpose of the study is to compare the outcome of OCT parameters for each...

OBJECTIVE To report the incidence of endophthalmitis, in addition to its clinical and microbiological aspects, after intravitreal injection of vascular-targeting agents. METHODS A retrospective review of a consecutive series of 10,142 intravitreal injections of vascular targeting agents (bevacizumab, ranibizumab, triamcinolone acetonide, and preservative-free triamcinolone acetonide) between ...

PURPOSE To compare the effects of intravitreal bevacizumab to those of triamcinolone acetonide injection for the treatment of macular edema secondary to branch retinal vein occlusion. METHODS This retrospective study included 50 eyes of 50 patients who received a single injection of intravitreal bevacizumab (1.25 mg/0.05 mL, 22 eyes) or triamcinolone acetonide (4 mg/0.1 mL, 28 eyes) as the on...

purpose: to determine if intravitreal injection of triamcinolone acetonide is safe and effective in the treatment of diabetic macular edema unresponsive to prior laser photocoagulation. methods: fifty-four eyes of 38 patients with clinically significant macular edema which had received at least two sessions of laser photocoagulation according to early treatment diabetic retinopathy study guidel...

purpose: to report treatment with intravitreal triamcinolone acetonide (ivta) in a patient with cystoid macular edema (cme) secondary to retinitis pigmentosa (rp). case report: a 22-year-old male patient with rp presented with progressive visual loss. visual acuity was 9/10 in the right eye and 10/10 in the left eye without refractive error. examination revealed cme in the right eye. after fail...

OBJECTIVE To evaluate the clinical outcome of an intravitreal injection of triamcinolone acetonide as treatment of diffuse diabetic macular edema. PARTICIPANTS This prospective, interventional, clinical case series study included 20 patients (26 eyes) who received an intravitreal injection of 25 mg of triamcinolone acetonide for treatment of diffuse diabetic macular edema. Mean +/- SD follow-...

PURPOSE To evaluate the effect of intravitreal triamcinolone acetonide in patients with diffuse diabetic macular edema on the visual acuity and intraocular pressure. To report the potential adverse events and to analyze the potential relationship between age and visual acuity and intraocular pressure variability. METHODS This clinical controlled study included 14 patients (28 eyes), 14 of the...

AIM To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide for treatment of diffuse diabetic macular oedema. METHODS Prospective, comparative, non-randomised clinical interventional study included 136 patients with diffuse diabetic macular oedema. Patients of the study group (97 eyes) received an intravitreal injection of 20-25 mg of triamcinolo...

AIM To evaluate prospectively immediate intraocular pressure (IOP) changes after the intravitreal injection of ranibizumab, 2 and 4mg triamcinolone acetonide. METHODS Patients who underwent intravitreal injection of 0.1mL (4mg) triamcinolone acetonide (TA, Group T4), 0.05mL (2mg) TA (Group T2) and 0.05mL (0.5mg) ranibizumab (Group R) comprised the study population. Overall, 229 eyes of 205 pa...

PURPOSE To evaluate the midterm anatomical and functional outcomes of intravitreal injection of low-dose triamcinolone acetonide in silicone oil-filled eyes as an adjunctive treatment for proliferative vitreoretinopathy. METHODS This is a retrospective interventional case series. Patients with proliferative vitreoretinopathy grade C or D received pars plana vitrectomy combined with silicone o...